🎉 M&A multiples are live!
Check it out!

RAPT Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for RAPT Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

RAPT Therapeutics Overview

About RAPT Therapeutics

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.


Founded

2015

HQ

United States of America
Employees

68

Website

rapt.com

Financials

LTM Revenue n/a

LTM EBITDA -$122M

EV

-$104M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

RAPT Therapeutics Financials

RAPT Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of -$122M.

In the most recent fiscal year, RAPT Therapeutics achieved revenue of n/a and an EBITDA of -$135M.

RAPT Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See RAPT Therapeutics valuation multiples based on analyst estimates

RAPT Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$126M -$135M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$83.8M -$117M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

RAPT Therapeutics Stock Performance

As of April 15, 2025, RAPT Therapeutics's stock price is $1.

RAPT Therapeutics has current market cap of $122M, and EV of -$104M.

See RAPT Therapeutics trading valuation data

RAPT Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$104M $122M XXX XXX XXX XXX $-2.44

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

RAPT Therapeutics Valuation Multiples

As of April 15, 2025, RAPT Therapeutics has market cap of $122M and EV of -$104M.

RAPT Therapeutics's trades at n/a LTM EV/Revenue multiple, and 0.9x LTM EBITDA.

Analysts estimate RAPT Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for RAPT Therapeutics and 10K+ public comps

RAPT Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$104M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.8x XXX XXX XXX
P/E -0.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 1.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get RAPT Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

RAPT Therapeutics Valuation Multiples

RAPT Therapeutics's NTM/LTM revenue growth is n/a

RAPT Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.0M for the same period.

Over next 12 months, RAPT Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate RAPT Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for RAPT Therapeutics and other 10K+ public comps

RAPT Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 7% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

RAPT Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

RAPT Therapeutics M&A and Investment Activity

RAPT Therapeutics acquired  XXX companies to date.

Last acquisition by RAPT Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . RAPT Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by RAPT Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About RAPT Therapeutics

When was RAPT Therapeutics founded? RAPT Therapeutics was founded in 2015.
Where is RAPT Therapeutics headquartered? RAPT Therapeutics is headquartered in United States of America.
How many employees does RAPT Therapeutics have? As of today, RAPT Therapeutics has 68 employees.
Who is the CEO of RAPT Therapeutics? RAPT Therapeutics's CEO is Dr. Brian Russell Wong, M.D.,PhD.
Is RAPT Therapeutics publicy listed? Yes, RAPT Therapeutics is a public company listed on NAS.
What is the stock symbol of RAPT Therapeutics? RAPT Therapeutics trades under RAPT ticker.
When did RAPT Therapeutics go public? RAPT Therapeutics went public in 2019.
Who are competitors of RAPT Therapeutics? Similar companies to RAPT Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of RAPT Therapeutics? RAPT Therapeutics's current market cap is $122M
What is the current EBITDA of RAPT Therapeutics? RAPT Therapeutics's last 12-month EBITDA is -$122M.
What is the current EV/EBITDA multiple of RAPT Therapeutics? Current EBITDA multiple of RAPT Therapeutics is 0.9x.
Is RAPT Therapeutics profitable? Yes, RAPT Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.